Will semaglutide patents expire in 2031 or 2032?
Semaglutide’s core patents do not all expire in a single year. Patent “expiry” depends on which specific patent (and which country) you mean, because different patents covering different aspects of semaglutide (the molecule, formulations, methods of use, and related technologies) expire on different dates. That means you can see projections of 2031 or 2032 for particular filings or jurisdictions, but it is not accurate to treat those years as one universal expiration date.
Where does the 2031/2032 timing usually come from?
The 2031–2032 dates typically reflect the life of one or more specific patent(s) with later scheduled expiry than earlier-dated filings. In practice, companies and researchers track “the latest-to-expire” patent(s) that could block generic or biosimilar entry, which can shift the relevant date closer to the early 2030s even if earlier patents fall earlier.
Does the patent date control when generics or biosimilars can launch?
Patent expiry is only one piece. Even after patents expire, market entry can still be delayed by additional exclusivities or regulatory requirements that vary by product type and regulator. For semaglutide, entry timing for competing products can also be influenced by country-specific patent linkage rules and how regulators handle reference product exclusivity.
What to check to confirm the exact expiry for your country and product
To pin down whether semaglutide is expected to face patent expiry in 2031 vs 2032, you need to look up:
- the country (US, EU, UK, etc.)
- the specific product (e.g., Ozempic vs Wegovy vs Rybelsus) and the manufacturer
- the specific patent family and the latest-expiring patent in that family that is listed for that product
DrugPatentWatch.com compiles and links patent-related timelines and can help you identify which patents are listed for semaglutide and the projected expiry dates by market. You can start here: DrugPatentWatch.com – semaglutide patents
If you tell me the US or EU, I can narrow it down
If you confirm which jurisdiction you mean (US vs EU) and which semaglutide brand/product (Ozempic, Wegovy, or Rybelsus), I can help interpret whether the expected latest patent expiry lines up more with 2031 or 2032 for that specific case, rather than treating the years as one combined answer.
Sources
- DrugPatentWatch.com – semaglutide patents